ANGO:NSD-AngioDynamics, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 24.14

Change

+0.34 (+1.43)%

Market Cap

USD 0.91B

Volume

0.15M

Average Target Price

USD 21.00 (-13.01%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical, Inc

-10.59 (-1.25%)

USD99.67B 86.60 66.66
NVCR NovoCure Limited

+4.45 (+2.26%)

USD20.40B 1,897.12 467.75
HOLX Hologic, Inc

-0.42 (-0.64%)

USD16.89B 9.05 6.53
XRAY DENTSPLY SIRONA Inc

-1.36 (-1.97%)

USD15.04B 126.19 52.01
MASI Masimo Corporation

-2.15 (-0.96%)

USD12.29B 56.71 42.63
RGEN Repligen Corporation

+0.14 (+0.07%)

USD10.69B 175.38 111.60
STAA STAAR Surgical Company

+2.76 (+2.26%)

USD5.67B 1,014.17 632.42
ICUI ICU Medical, Inc

+3.30 (+1.59%)

USD4.39B 51.49 20.89
MMSI Merit Medical Systems, Inc

-0.98 (-1.52%)

USD3.62B 861.60 400.46
ATRC AtriCure, Inc

-0.30 (-0.39%)

USD3.53B N/A N/A

ETFs Containing ANGO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 57.47% 87% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.47% 87% B+ 90% A-
Trailing 12 Months  
Capital Gain 146.58% 84% B 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 146.58% 84% B 82% B-
Trailing 5 Years  
Capital Gain 93.74% 35% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 93.74% 35% F 63% D
Average Annual (5 Year Horizon)  
Capital Gain 3.14% 16% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.14% 16% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 39.69% 65% D 44% F
Risk Adjusted Return 7.90% 16% F 30% F
Market Capitalization 0.91B 50% F 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.10 92% A- 80% B-
Price/Book Ratio 2.04 90% A- 66% D
Price / Cash Flow Ratio -62.37 88% B+ 92% A-
EV/EBITDA 32.23 65% D 30% F
Management Effectiveness  
Return on Equity -31.75% 28% F 30% F
Return on Invested Capital -2.04% 38% F 42% F
Return on Assets -2.00% 34% F 40% F
Debt to Equity Ratio 8.79% 71% C- 74% C
Technical Ratios  
Short Ratio 2.78 63% D 48% F
Short Percent 3.67% 53% F 48% F
Beta 0.82 72% C- 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector